Lipid Nanocarriers for Hyperproliferative Skin Diseases

Hyperproliferative skin diseases (HSD) are a group of diseases that include cancers, pre-cancerous lesions and diseases of unknown etiology that present different skin manifestations in terms of the degree and distribution of the injuries. Anti-proliferative agents used to treat these diseases are s...

Descripción completa

Detalles Bibliográficos
Autores: Souto, Eliana B., de Souza, Ana Luiza R., Dos Santos, Fernanda K., Sánchez-López, E. (Elena), Cano Fernández, Amanda, Zielinska, Aleksandra, Staszewski, Rafal, Karczewski, Jacek, Gremiao, Maria Palmira D, Chorilli, Marlus
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/183722
Acceso en línea:https://hdl.handle.net/2445/183722
Access Level:acceso abierto
Palabra clave:Pell
Nanopartícules
Càncer de pell
Skin
Nanoparticles
Skin cancer
id ES_7edd3d87104b4f1ffc517fcfd95bdb00
oai_identifier_str oai:recercat.cat:2445/183722
network_acronym_str ES
network_name_str España
repository_id_str
spelling Lipid Nanocarriers for Hyperproliferative Skin DiseasesSouto, Eliana B.de Souza, Ana Luiza R.Dos Santos, Fernanda K.Sánchez-López, E. (Elena)Cano Fernández, AmandaZielinska, AleksandraStaszewski, RafalKarczewski, JacekGremiao, Maria Palmira DChorilli, MarlusPellNanopartículesCàncer de pellSkinNanoparticlesSkin cancerHyperproliferative skin diseases (HSD) are a group of diseases that include cancers, pre-cancerous lesions and diseases of unknown etiology that present different skin manifestations in terms of the degree and distribution of the injuries. Anti-proliferative agents used to treat these diseases are so diverse, including 5-aminolevulinic acid, 5-fluorouracil, imiquimod, methotrexate, paclitaxel, podophyllotoxin, realgar, and corticosteroids in general. These drugs usually have low aqueous solubility, which consequently decreases skin permeation. Thus, their incorporation in lipid nanocarriers has been proposed with the main objective to increase the effectiveness of topical treatment and reduce side effects. This manuscript aims to describe the advantages of using lipid nanoparticles and liposomes that can be used to load diversity of chemically different drugs for the treatment of HSD. Keywords: lipid nanoparticles; liposomes; hyperproliferative skin diseases; antiproliferative drugs; skin cancerMDPI2022202220212022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/183722Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.3390/cancers13225619Cancers, 2021, vol. 13, num. 5619https://doi.org/10.3390/cancers13225619cc-by (c) Souto, Eliana B. et al., 2021https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1837222026-05-29T05:05:01Z
dc.title.none.fl_str_mv Lipid Nanocarriers for Hyperproliferative Skin Diseases
title Lipid Nanocarriers for Hyperproliferative Skin Diseases
spellingShingle Lipid Nanocarriers for Hyperproliferative Skin Diseases
Souto, Eliana B.
Pell
Nanopartícules
Càncer de pell
Skin
Nanoparticles
Skin cancer
title_short Lipid Nanocarriers for Hyperproliferative Skin Diseases
title_full Lipid Nanocarriers for Hyperproliferative Skin Diseases
title_fullStr Lipid Nanocarriers for Hyperproliferative Skin Diseases
title_full_unstemmed Lipid Nanocarriers for Hyperproliferative Skin Diseases
title_sort Lipid Nanocarriers for Hyperproliferative Skin Diseases
dc.creator.none.fl_str_mv Souto, Eliana B.
de Souza, Ana Luiza R.
Dos Santos, Fernanda K.
Sánchez-López, E. (Elena)
Cano Fernández, Amanda
Zielinska, Aleksandra
Staszewski, Rafal
Karczewski, Jacek
Gremiao, Maria Palmira D
Chorilli, Marlus
author Souto, Eliana B.
author_facet Souto, Eliana B.
de Souza, Ana Luiza R.
Dos Santos, Fernanda K.
Sánchez-López, E. (Elena)
Cano Fernández, Amanda
Zielinska, Aleksandra
Staszewski, Rafal
Karczewski, Jacek
Gremiao, Maria Palmira D
Chorilli, Marlus
author_role author
author2 de Souza, Ana Luiza R.
Dos Santos, Fernanda K.
Sánchez-López, E. (Elena)
Cano Fernández, Amanda
Zielinska, Aleksandra
Staszewski, Rafal
Karczewski, Jacek
Gremiao, Maria Palmira D
Chorilli, Marlus
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Pell
Nanopartícules
Càncer de pell
Skin
Nanoparticles
Skin cancer
topic Pell
Nanopartícules
Càncer de pell
Skin
Nanoparticles
Skin cancer
description Hyperproliferative skin diseases (HSD) are a group of diseases that include cancers, pre-cancerous lesions and diseases of unknown etiology that present different skin manifestations in terms of the degree and distribution of the injuries. Anti-proliferative agents used to treat these diseases are so diverse, including 5-aminolevulinic acid, 5-fluorouracil, imiquimod, methotrexate, paclitaxel, podophyllotoxin, realgar, and corticosteroids in general. These drugs usually have low aqueous solubility, which consequently decreases skin permeation. Thus, their incorporation in lipid nanocarriers has been proposed with the main objective to increase the effectiveness of topical treatment and reduce side effects. This manuscript aims to describe the advantages of using lipid nanoparticles and liposomes that can be used to load diversity of chemically different drugs for the treatment of HSD. Keywords: lipid nanoparticles; liposomes; hyperproliferative skin diseases; antiproliferative drugs; skin cancer
publishDate 2021
dc.date.none.fl_str_mv 2021
2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/183722
url https://hdl.handle.net/2445/183722
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3390/cancers13225619
Cancers, 2021, vol. 13, num. 5619
https://doi.org/10.3390/cancers13225619
dc.rights.none.fl_str_mv cc-by (c) Souto, Eliana B. et al., 2021
https://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Souto, Eliana B. et al., 2021
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411781457215488
score 15,811543

Similares en LA Referencia